Please login to the form below

Not currently logged in
Email:
Password:

HSDD

This page shows the latest HSDD news and features for those working in and with pharma, biotech and healthcare.

Valeant swoops on Sprout to claim female sexual disorder drug

Valeant swoops on Sprout to claim female sexual disorder drug

Comes in the same week that firm gained US approval for its ‘little pink pill’

Latest news

  • FDA approves first female sexual disorder drug FDA approves first female sexual disorder drug

    The FDA has approved the drug for generalised hypoactive sexual desire disorder (HSDD) in premenopausal women and said this is the first time that a drug has been approved for sexual

  • FDA panel backs Sprout Pharma's 'female Viagra' FDA panel backs Sprout Pharma's 'female Viagra'

    FDA panel backs Sprout Pharma's 'female Viagra'. Could be approved for HSDD in pre-menopausal women. ... If given the nod by the FDA, flibanserin would become the first ever drug approved for HSDD, although other companies are working in this area.

  • Female sexual dysfunction therapy pipeline Female sexual dysfunction therapy pipeline

    HSDD is thought to be the most prevalent sexual disorder in women of all ages. ... The randomised trials were conducted in the US and Canada in surgically menopausal women with HSDD.

  • Lamb to the slaughter

    The Daily Telegraph ran a piece on Hypoactive Sexual Desire Disorder (HSDD), usually referred to as 'Female Sexual Dysfunction'.

  • Trials show effectiveness for HSDD

    HSDD is a medical condition characterised by a decrease in sexual desire associated with marked distress and/or interpersonal difficulties. ... Flibanserin is a novel, non-hormonal compound, that has been investigated as a treatment for pre-menopausal

More from news
Approximately 3 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Grace Communications

Grace Communications is a creative agency specialising in healthcare communication and understanding people's personality types....

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics